|
1
|
Steele JR, Italiano CJ, Phillips CR, Violi JP, Pu L, Rodgers KJ, Padula MP. Correction: Steele et al. Misincorporation Proteomics Technologies: A Review. Proteomes 2021, 9, 2. Proteomes 2022; 10:proteomes10020022. [PMID: 35736802 PMCID: PMC9227081 DOI: 10.3390/proteomes10020022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Accepted: 05/16/2022] [Indexed: 11/16/2022] Open
Abstract
In the original publication, there was a mistake in Table 2 as published [...].
Collapse
Affiliation(s)
- Joel R. Steele
- Proteomics Core Facility and School of Life Sciences, The University of Technology Sydney, Ultimo, NSW 2007, Australia; (J.R.S.); (J.P.V.)
- Neurotoxin Research Group, School of Life Sciences, The University of Technology Sydney, Ultimo, NSW 2007, Australia; (C.J.I.); (C.R.P.); (L.P.); (K.J.R.)
| | - Carly J. Italiano
- Neurotoxin Research Group, School of Life Sciences, The University of Technology Sydney, Ultimo, NSW 2007, Australia; (C.J.I.); (C.R.P.); (L.P.); (K.J.R.)
| | - Connor R. Phillips
- Neurotoxin Research Group, School of Life Sciences, The University of Technology Sydney, Ultimo, NSW 2007, Australia; (C.J.I.); (C.R.P.); (L.P.); (K.J.R.)
| | - Jake P. Violi
- Proteomics Core Facility and School of Life Sciences, The University of Technology Sydney, Ultimo, NSW 2007, Australia; (J.R.S.); (J.P.V.)
- Neurotoxin Research Group, School of Life Sciences, The University of Technology Sydney, Ultimo, NSW 2007, Australia; (C.J.I.); (C.R.P.); (L.P.); (K.J.R.)
| | - Lisa Pu
- Neurotoxin Research Group, School of Life Sciences, The University of Technology Sydney, Ultimo, NSW 2007, Australia; (C.J.I.); (C.R.P.); (L.P.); (K.J.R.)
| | - Kenneth J. Rodgers
- Neurotoxin Research Group, School of Life Sciences, The University of Technology Sydney, Ultimo, NSW 2007, Australia; (C.J.I.); (C.R.P.); (L.P.); (K.J.R.)
| | - Matthew P. Padula
- Proteomics Core Facility and School of Life Sciences, The University of Technology Sydney, Ultimo, NSW 2007, Australia; (J.R.S.); (J.P.V.)
- Correspondence:
| |
Collapse
|
|
2
|
Sobel RA, Albertelli M, Hinojoza JR, Eaton MJ, Grimes KV, Rubenstein E. Azetidine-2-Carboxylic Acid-Induced Oligodendrogliopathy: Relevance to the Pathogenesis of Multiple Sclerosis. J Neuropathol Exp Neurol 2022; 81:414-433. [PMID: 35521963 PMCID: PMC9123080 DOI: 10.1093/jnen/nlac028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
The naturally occurring imino acid azetidine-2-carboxylic acid (Aze) is consumed by humans and can be misincorporated in place of proline in myelin basic protein (MBP) in vitro. To determine Aze effects on the mammalian CNS in vivo, adult CD1 mice were given Aze orally or intraperitoneally. Clinical signs reminiscent of MBP-mutant mice occurred with 600 mg/kg Aze exposure. Aze induced oligodendrocyte (OL) nucleomegaly and nucleoplasm clearing, dilated endoplasmic reticulum, cytoplasmic vacuolation, abnormal mitochondria, and Aze dose-dependent apoptosis. Immunohistochemistry demonstrated myelin blistering and nuclear translocation of unfolded protein response (UPR)/proinflammatory molecules (ATF3, ATF4, ATF6, eIF2α, GADD153, NFκB, PERK, XBP1), MHC I expression, and MBP cytoplasmic aggregation in OL. There were scattered microglial nodules in CNS white matter (WM); other CNS cells appeared unaffected. Mice given Aze in utero and postnatally showed more marked effects than their dams. These OL, myelin, and microglial alterations are found in normal-appearing WM (NAWM) in multiple sclerosis (MS) patients. Thus, Aze induces a distinct oligodendrogliopathy in mice that recapitulates MS NAWM pathology without leukocyte infiltration. Because myelin proteins are relatively stable throughout life, we hypothesize that Aze misincorporation in myelin proteins during myelinogenesis in humans results in a progressive UPR that may be a primary process in MS pathogenesis.
Collapse
Affiliation(s)
- Raymond A Sobel
- From the Laboratory Service, Veterans Affairs Health Care System, Palo Alto, California, USA.,Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
| | - Megan Albertelli
- Department of Comparative Medicine, Stanford University School of Medicine, Stanford, California, USA
| | - Julian R Hinojoza
- From the Laboratory Service, Veterans Affairs Health Care System, Palo Alto, California, USA.,Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
| | - Mary Jane Eaton
- From the Laboratory Service, Veterans Affairs Health Care System, Palo Alto, California, USA.,Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
| | - Kevin V Grimes
- Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California, USA
| | - Edward Rubenstein
- Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
| |
Collapse
|
|
3
|
Steele JR, Strange N, Rodgers KJ, Padula MP. A Novel Method for Creating a Synthetic L-DOPA Proteome and In Vitro Evidence of Incorporation. Proteomes 2021; 9:24. [PMID: 34073856 PMCID: PMC8162537 DOI: 10.3390/proteomes9020024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2021] [Revised: 05/02/2021] [Accepted: 05/18/2021] [Indexed: 11/16/2022] Open
Abstract
Proteinopathies are protein misfolding diseases that have an underlying factor that affects the conformation of proteoforms. A factor hypothesised to play a role in these diseases is the incorporation of non-protein amino acids into proteins, with a key example being the therapeutic drug levodopa. The presence of levodopa as a protein constituent has been explored in several studies, but it has not been examined in a global proteomic manner. This paper provides a proof-of-concept method for enzymatically creating levodopa-containing proteins using the enzyme tyrosinase and provides spectral evidence of in vitro incorporation in addition to the induction of the unfolded protein response due to levodopa.
Collapse
Affiliation(s)
- Joel Ricky Steele
- Proteomics Core Facility and School of Life Sciences, The University of Technology Sydney, Ultimo, NSW 2007, Australia;
- Neurotoxin Research Group, School of Life Sciences, The University of Technology Sydney, Ultimo, NSW 2007, Australia;
| | - Natalie Strange
- School of Life Sciences, The University of Technology Sydney, Ultimo, NSW 2007, Australia;
| | - Kenneth J. Rodgers
- Neurotoxin Research Group, School of Life Sciences, The University of Technology Sydney, Ultimo, NSW 2007, Australia;
| | - Matthew P. Padula
- Proteomics Core Facility and School of Life Sciences, The University of Technology Sydney, Ultimo, NSW 2007, Australia;
| |
Collapse
|